{
    "clinical_study": {
        "@rank": "74147", 
        "brief_summary": {
            "textblock": "A clinical study to determine the efficacy and safety of MK0869 in the treatment of\n      depression."
        }, 
        "brief_title": "Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)", 
        "completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "The duration of treatment is 8 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Major depressive disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "495", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 2, 2002", 
        "id_info": {
            "nct_id": "NCT00034944", 
            "org_study_id": "0869-063", 
            "secondary_id": "2006_403"
        }, 
        "intervention": [
            {
                "intervention_name": "MK0869, aprepitant", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Comparator: placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aprepitant"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 19, 2013", 
        "official_title": "A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "HAMD-17 total score at week 8. Tolerability."
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00034944"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "16248986", 
            "citation": "Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, Beebe K, Reines S. Lack of Efficacy of the Substance P (Neurokinin(1) Receptor) Antagonist Aprepitant in the Treatment of Major Depressive Disorder. Biol Psychiatry. 2005 Oct 21; [Epub ahead of print]"
        }, 
        "secondary_outcome": {
            "measure": "CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score."
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }, 
    "geocoordinates": {}
}